BCL6 and neoplasm: In addition, MED12 overexpression interferes with the VDR/BCL6/p53 signaling axis, inhibits the tumor suppressor function of p53, enhances the pro-survival role of BCL6, and drives the malignant progression of glioblastoma [82].